We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Stoke Therapeutics Inc (STOK) USD0.0001

Sell:$11.66 Buy:$11.68 Change: $0.38 (3.36%)
NASDAQ:1.03%
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$11.66
Buy:$11.68
Change: $0.38 (3.36%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$11.66
Buy:$11.68
Change: $0.38 (3.36%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The Company is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.

Contact details

Address:
45 WIGGINS AVENUE
BEDFORD
01730
United States
Telephone:
+1 (781) 4308200
Website:
https://www.stoketherapeutics.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
STOK
ISIN:
US86150R1077
Market cap:
$588.46 million
Shares in issue:
52.97 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Edward Kaye
    Chief Executive Officer, Director
  • Thomas Leggett
    Chief Financial Officer
  • Jonathan Allan
    General Counsel, Corporate Secretary
  • Jason Hoitt
    Chief Commercial Officer
  • Eric Olson
    Chief Business Officer
  • Barry Ticho
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.